Mi SciELO
Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Citado por Google
- Similares en SciELO
- Similares en Google
Compartir
Revista de la OFIL
versión On-line ISSN 1699-714Xversión impresa ISSN 1131-9429
Resumen
TEJEDOR TEJADA, E; TEJEDOR-TEJADA, J y VERDEJO RECHE, F. Experience with teduglutide as a treatment for short bowel síndrome. Rev. OFIL·ILAPHAR [online]. 2023, vol.33, n.1, pp.95-97. Epub 27-Nov-2023. ISSN 1699-714X. https://dx.doi.org/10.4321/s1699-714x2023000100017.
Short bowel syndrome (SBS) is a metabolic disorder that causes malabsorption. It affects patients who have anatomically or functionally lost part of their intestine1. In adults, the main cause is primary or secondary intestinal ischemia and less frequently it may be a consequence of inflammatory bowel disease or radicular enteritis. Mid-term mortality is high due to the high risk of complications from catheter-related sepsis, bacterial overgrowth or liver failure associated with parenteral nutrition (PN)2.
Palabras clave : Glucagon-like peptide 2; intestinal adaptation; intestinal failure; nutritional status; parenteral nutrition; teduglutide.